| Literature DB >> 29108375 |
Sehoon Park1,2, Jung Nam An3, Jung Pyo Lee3,4, Yun Kyu Oh3,4, Dong Ki Kim4,2, Kwon Wook Joo4,2, Yon Su Kim1,2, Chun Soo Lim3,4.
Abstract
Recent evidence for the clinical significance of postoperative hyponatremia after urologic surgeries remains scarce. We examined the incidence, risk factors, and outcomes of electrolyte imbalance in urologic surgery. Patients with newly developed hyponatremia, defined as a sodium level lower than 135 mEq/L within 7 days after surgery, were included in our study group. The primary outcome was progression to end-stage renal disease (ESRD). Secondary outcome was composition of progression to ESRD and creatinine doubling/eGFR halving from baseline. A survival analysis with a multivariable Cox proportional hazard model was performed. We included 9,206 cases of bladder, prostate, ureter, and kidney surgery. Incidence of new-onset postoperative hyponatremia was 15.4% (1,414/9,206). Postoperative hyponatremia mostly developed in patients with high-risk perioperative characteristics. The development of postoperative hyponatremia was independently associated with progression to ESRD (adjusted HR 1.343, 95% CI 1.082-1.680, P = 0.007). The secondary outcome was also related to the electrolyte imbalance in prostate (adjusted HR 1.729, 95% CI 1.145-2.612, P = 0.009) and kidney (adjusted HR 1.339, 95% CI 1.099-1.632, P = 0.004) surgery. Postoperative hyponatremia in urologic surgery was a common electrolyte imbalance in patients with high-risk perioperative status, and associated with worse renal prognosis.Entities:
Keywords: acute kidney injury; end stage renal disease; hyponatremia; surgery; urology
Year: 2017 PMID: 29108375 PMCID: PMC5668108 DOI: 10.18632/oncotarget.20326
Source DB: PubMed Journal: Oncotarget ISSN: 1949-2553
Figure 1Flow diagram of the study population
Figure 2Distribution of lowest serum Na levels in the preoperative and postoperative periods in the study population
The X-axis shows the serum Na level and Y-axis shows the proportion of patients identified with the serum Na level. Light grey bars indicate the distribution of preoperative Na (PreOp Na), and dark grey bars indicate the distribution of postoperative Na (PostOp Na) values of the study population. Dotted vertical line shows a serum Na level of 135 mEq/L, which was the criterion for hyponatremia in the study.
Baseline characteristics of study patients
| New-onset hyponatremia (+) | New-onset hyponatremia (-) | ||
|---|---|---|---|
| Age (years) | 65 (54–72) | 65 (54–71) | 0.065 |
| Sex (Female) | 375 (26.5) | 1657 (21.3) | < 0.001 |
| Body mass index (kg/m2) | 24.0 (22.1–26.0) | 24.3 (22.3–26.4) | < 0.001 |
| Baseline laboratory results | |||
| sCr (mg/dL) | 0.92 (0.77–1.1) | 0.92 (0.80–1.08) | 0.229 |
| eGFR (mL/min/1.73 m2) | 68.7 (52.9–90.5) | 67.6 (54.1–86.5) | 0.164 |
| Hemoglobin (g/dL) | 13.2 (11.6–14.4) | 13.6 (12.3–14.7) | < 0.001 |
| Sodium (mEq/L) | 140 (138–141) | 141 (139–142) | < 0.001 |
| Underlying comorbidities | |||
| Cancer | 1111 (78.6) | 5691 (73.0) | < 0.001 |
| Hypertension | 551 (39.0) | 2630 (33.8) | < 0.001 |
| Diabetes mellitus | 298 (21.1) | 1441 (18.5) | 0.023 |
| Chronic kidney disease | 502 (35.5) | 2730 (35.0) | 0.735 |
| Liver cirrhosis | 67 (4.7) | 312 (4.0) | 0.201 |
| Heart failure | 104 (7.4) | 491 (6.3) | 0.138 |
| Preoperative use of | |||
| ACE I/ARBs | 165 (11.7) | 853 (10.9) | 0.426 |
| Diuretics | 150 (10.6) | 723 (9.3) | 0.116 |
| SSRI/SNRIs | 14 (1.0) | 97 (1.2) | 0.419 |
| NSAIDs | 273 (19.3) | 1649 (21.2) | 0.114 |
| Antipsychotics | 11 (0.8) | 43 (0.6) | 0.306 |
| Benzodiazepines | 42 (3.0) | 242 (3.1) | 0.786 |
| Antiepileptic agents | 46 (3.3) | 211 (2.7) | 0.252 |
| Proton pump inhibitor | 95 (6.7) | 578 (7.4) | 0.353 |
| Thyroidal hormones | 19 (1.3) | 92 (1.2) | 0.605 |
| Anti–thyroidal medications | 1 (0.1) | 13 (0.2) | 0.393 |
| Oral steroids | 46 (3.3) | 282 (3.6) | 0.495 |
sCr, serum creatinine, eGFR, estimated glomerular filtration rate, ACE I, angiotensin converting enzyme inhibitor, ARB, angiotensin receptor blocker, SSRI, selective-serotonin reuptake inhibitor, SNRI, serotonin norepinephrine reuptake inhibitor, NSAID, non-steroidal anti-inflammatory drug
Values were presented as n (%) for categorical variables, and median (25% to 75% interquartile) for continuous variables (all data in the table showed non-normal distribution).
Categories of operations and incidence of hyponatremia
| Operation category | aIncidence of hyponatremia | New-onset hyponatremia (+) | New-onset hyponatremia (-) | |
|---|---|---|---|---|
| Bladder | 11.1% | 201 (14.2) | 1,613 (20.7) | < 0.001 |
| TUR-B | 8.1% | 86 (6.1) | 980 (12.6) | |
| Cystolithotripsy | 4.8% | 3 (0.2) | 60 (0.8) | |
| Cystectomy | 18.9% | 101 (7.1) | 433 (5.6) | |
| Cystocele repair | 1.8% | 1 (0.1) | 60 (0.8) | |
| Transurethral coagulation | 20% | 3 (0.2) | 12 (0.2) | |
| Cystostomy | 0% | 0 (0.0) | 4 (0.1) | |
| Other cystoscopy | 6.1% | 1 (0.1) | 13 (0.2) | |
| miscellaneous | 10.5% | 6 (0.4) | 51 (0.7) | |
| Prostate | 10.9% | 323 (22.8) | 2,634 (33.8) | < 0.001 |
| TUR-P, HoLEP etc. | 8.8% | 52 (3.7) | 540 (6.9) | |
| Radical prostatectomy | 11.5% | 271 (19.2) | 2,084 (26.7) | |
| miscellaneous | 0% | 0 (0.0) | 10 (0.1) | |
| Ureter | 9.8% | 59 (4.2) | 540 (6.9) | < 0.001 |
| Stone removal | 9.1% | 30 (2.1) | 301 (3.9) | |
| Ureterectomy | 22.2% | 4 (0.3) | 14 (0.2) | |
| Ureterotomy | 7.8% | 4 (0.3) | 47 (0.6) | |
| Ureteral stent insertion/removal | 13% | 13 (0.9) | 87 (1.1) | |
| Other ureteroscopy | 5.4% | 3 (0.2) | 56 (0.7) | |
| miscellaneous | 12.5% | 5 (0.4) | 35 (0.4) | |
| Kidney | 21.7% | 831 (58.8) | 3,005 (38.8) | < 0.001 |
| Partial nephrectomy | 20.0% | 278 (19.7) | 1,110 (14.2) | |
| Unilateral radical nephrectomy | 24.9% | 525 (37.1) | 1,583 (20.3) | |
| Bilateral nephrectomy | 0% | 0 (0.0) | 1 (0.0) | |
| Nephrolithotomy | 8.8% | 27 (1.9) | 280 (3.6) | |
| Pyeloplasty | 3.1% | 1 (0.1) | 31 (0.4) |
TUR-B, transurethral bladder resection, TUR-P, transurethral prostate resection, HoLEP, Holmium Laser Enucleation of the prostate
Included numbers of surgery cases were presented as n (%).
aIncidence of postoperative hyponatremia in each subtypes of surgery (in each row) was shown.
Perioperative findings of study patients
| New-onset hyponatremia (+) | New-onset hyponatremia (-) | ||
|---|---|---|---|
| Surgery type | 0.906 | ||
| Open surgery | 713 (50.4) | 3936 (50.5) | |
| Laparoscopic surgery | 183 (12.9) | 1006 (12.9) | |
| Endoscopic surgery | 335 (23.7) | 1891 (24.3) | |
| Robot-assisted surgery | 183 (12.9) | 959 (12.3) | |
| Anesthesia type | 0.067 | ||
| Spinal | 117 (8.4) | 819 (10.6) | |
| General | 1,267 (91.0) | 6,791 (88.3) | |
| Others (MAC, epidural, etc.) | 8 (0.6) | 80 (1.1) | |
| ASA classification | 0.002 | ||
| 0 | 4 (0.3) | 29 (0.4) | |
| 1 | 455 (33.3) | 2,629 (34.7) | |
| 2 | 793 (58.0) | 4,470 (59.1) | |
| 3 | 112 (8.2) | 434 (5.7) | |
| ≥ 4 | 3 (0.2) | 4 (0.1) | |
| NYHA classification | 0.092 | ||
| 1 | 1,182 (89.5) | 6,683 (91.2) | |
| 2 | 117 (8.9) | 574 (7.8) | |
| ≥ 3 | 22 (1.7) | 73 (1.0) | |
| Anesthesia time (minutes) | 190 (145–250) | 175 (115–235) | < 0.001 |
| < 120 | 194 (14.0) | 1994 (26.0) | |
| ≥ 120, and < 180 | 381 (27.4) | 1894 (24.7) | |
| ≥ 180 | 813 (58.6) | 3777 (49.3) | |
| In non-general anesthesia (minutes) | 145 (85–170) | 115 (60–160) | < 0.001 |
| In general anesthesia (minutes) | 200 (150–255) | 185 (125–245) | < 0.001 |
| Surgical time (minutes) | 147 (109–200) | 135 (77–190) | < 0.001 |
| < 120 | 438 (31.6) | 3176 (41.5) | |
| ≥ 120, and < 180 | 466 (33.6) | 2264 (29.5) | |
| ≥ 180 | 483 (34.8) | 2222 (29.0) | |
| In non-general anesthesia (minutes) | 109 (50–135) | 85 (35–125) | 0.001 |
| In general anesthesia (minutes) | 155 (110–209) | 140 (87–197) | < 0.001 |
| Emergency operation | 3 (0.2) | 25 (0.3) | 0.505 |
| Intraoperative use of intravenous fluid | |||
| Balanced salt solution | |||
| Number of cases | 374 (26.4) | 2,065 (26.5) | 0.968 |
| Amount of fluid use (mL) | 800 (500–1,200) | 800 (500–1,150) | 0.863 |
| Hartman solution | |||
| Number of cases | 1,175 (83.1) | 6,244 (80.1) | 0.010 |
| Amount of fluid use (mL) | 850 (600–1,300) | 800 (500–1,200) | < 0.001 |
| Normal saline | |||
| Number of cases | 531 (37.6) | 2,357 (30.2) | < 0.001 |
| Amount of fluid use (mL) | 700 (400–1,000) | 700 (400–1,000) | 0.136 |
| Hydroxyethyl starch | |||
| Number of cases | 469 (33.2) | 2,147 (27.6) | < 0.001 |
| Amount of fluid use (mL) | 500 (500–825) | 500 (500–1,000) | 0.394 |
| Intraoperative RBC transfusion | < 0.001 | ||
| 1–2 pack | 114 (8.1) | 347 (4.5) | |
| 3–4 pack | 38 (2.7) | 125 (1.6) | |
| 5–9 pack | 9 (0.6) | 43 (0.6) | |
| > 9 pack | 3 (0.2) | 9 (0.1) | |
| Inotropic agents use at Op day | 18 (1.3) | 118 (1.5) | 0.489 |
MAC, monitored anesthesia care, RBC, red blood cell, Op, operation
Values were presented as n (%) for categorical variables, and median (25% to 75% interquartile) for continuous variables (all data in the table showed non-normal distribution).
Postoperative findings of study patients
| New-onset hyponatremia (+) | New-onset hyponatremia (-) | ||
|---|---|---|---|
| Acute kidney injury | < 0.001 | ||
| Stage 1 | 415 (30.3) | 1,410 (20.9) | |
| Stage 2 | 26 (1.9) | 78 (1.2) | |
| Stage 3 | 49 (3.6) | 151 (2.2) | |
| sCr (mg/dL) | 1.10 (0.91–1.40) | 1.03 (0.90–1.28) | < 0.001 |
| eGFR (mL/min/1.73 m2) | 55.0 (40.0–74.6) | 59.0 (45.5–74.9) | < 0.001 |
| Sodium (mEq/L) | 133 (132–134) | 137 (136–139) | < 0.001 |
| Hemoglobin (g/dL) | 10.9 (9.6–12.0) | 11.4 (10.2–12.6) | < 0.001 |
| Sodium decrement (mEq/L) | 7.0 (9.0–5.0) | 3.0 (5.0–2.0) | < 0.001 |
| Hemoglobin decrement (g/dL) | 2.2 (1.1–3.3) | 2.1 (1.1–3.2) | 0.038 |
| Body weight change (kg) | 0.0 (–1.0 – 1.0) | 0.0 (–1.0 – 1.0) | 0.511 |
| Days of hospital stay (days) | 6 (5–9) | 5 (4–8) | < 0.001 |
| Postoperative ICU admission | 14 (1.0) | 48 (0.6) | 0.114 |
sCr, serum creatinine, eGFR, estimated glomerular filtration rate, ICU, intensive care unit.
Values were presented as n (%) for categorical variables, and median (25% to 75% interquartile) for continuous variables (all data in the table showed non-normal distribution).
Risk factors for new-onset postoperative hyponatremia
| Variables | bAdjusted OR (95% CI) | |
|---|---|---|
| Age (1-year increment) | 1.013 (1.007–1.018) | < 0.001 |
| Female sex (vs. male) | 1.216 (1.045–1.414) | 0.011 |
| Body mass index (1 kg/m2 increment) | 0.999 (0.999–1.000) | < 0.001 |
| Cancer (vs. no) | 1.248 (1.067–1.459) | 0.006 |
| Hypertension (vs. no) | 1.139 (0.995–1.305) | 0.060 |
| Diabetes mellitus (vs. no) | 1.317 (1.116–1.554) | 0.001 |
| Baseline Na (1 mEq/L increment) | 0.829 (0.803–0.856) | < 0.001 |
| Baseline anemia (hemoglobin < 12 g/dL) | 1.311 (1.139–1.509) | < 0.001 |
| Kidney operation (vs. other surgery) | 2.765 (2.388–3.202) | < 0.001 |
| Surgery time (1-hour increment) | 1.109 (1.063–1.157) | < 0.001 |
| NYHA classification (≥ 2) | 1.159 (0.905–1.485) | 0.243 |
| ASA classification (≥ class III) | 1.621 (1.372–1.915) | < 0.001 |
| Use of Hartman solution (vs. no) | 1.319 (1.107–1.573) | 0.002 |
| Use of hydroxyethyl starch (vs. no) | 1.139 (0.978–1.325) | 0.094 |
| Use of normal saline (vs. no) | 1.236 (1.079–1.416) | 0.002 |
| Transfusion amount of RBC (1-pack increment) | 1.021 (0.984–1.060) | 0.274 |
| Acute kidney injury (vs. no acute kidney injury) | ||
| Stage 1 | 1.433 (1.232–1.666) | < 0.001 |
| Stage 2 | 1.649 (1.023–2.657) | 0.040 |
| Stage 3 | 1.724 (1.214–2.447) | 0.002 |
OR, odds ratio, CI, confidence interval
bAdjusted simultaneously with all variables in the table and multivariable logistic regression test was performed.
Figure 3Cox proportional hazard models with panelized smoothing splines showing the association of postoperative Na level and risk of progression to ESRD
The hazard ratio was calculated using the Na level with lowest risk for ESRD as the reference value. The X-axis shows the lowest postoperative sodium level within 7 days from surgery and the Y-axis shows the hazard ratios. Broken lines signify 95% confidence interval. The vertical broken line is drawn at a sodium level of 135 mEq/L, which was the criterion used to define postoperative hyponatremia in the study.
Clinical characteristics related to long-term renal prognosis in the study cohort
| Variables | aAdjusted HR | 95% CI | |
|---|---|---|---|
| Age (years) | 1.033 | 1.027–1.039 | < 0.001 |
| Female sex | 0.700 | 0.593–0.827 | < 0.001 |
| Hypertension | 1.025 | 0.897–1.172 | 0.713 |
| Diabetes mellitus | 1.427 | 1.216–1.675 | < 0.001 |
| Preoperative severe anemia | 1.282 | 1.036–1.586 | 0.022 |
| Preoperative creatinine (mg/dL) | 2.022 | 1.711–2.389 | < 0.001 |
| Postoperative creatinine (mg/dL) | 1.010 | 1.004–1.017 | 0.003 |
| Intraoperative use of normal saline | 1.030 | 0.905–1.172 | 0.656 |
| Postoperative hyponatremia | 1.331 | 1.148–1.542 | < 0.001 |
HR, hazard ratio, CI, confidence interval, hb, hemoglobin
aAdjusted with organ of surgery (bladder, prostate, ureter, kidney), surgery type (open, laparoscopic, endoscopic, and robot-assisted surgery), age, sex, history of hypertension, diabetes mellitus, preoperative severe anemia, intraoperative use of normal saline, preoperative and postoperative serum creatinine level.
Association of postoperative hyponatremia and long-term renal prognosis in various subgroups
| Subpopulation | aAdjusted HR | 95% CI | |
|---|---|---|---|
| Age ≥ 70 ( | 1.088 | 0.861–1.376 | 0.479 |
| Age 50–70 ( | 1.490 | 1.205–1.843 | < 0.001 |
| Age < 50 ( | 1.918 | 1.245–2.957 | 0.003 |
| Female ( | 1.227 | 0.873–1.725 | 0.239 |
| Male ( | 1.362 | 1.156–1.605 | < 0.001 |
| eGFR < 60 ( | 1.299 | 1.066–1.584 | 0.010 |
| eGFR ≥ 60 ( | 1.425 | 1.142–1.778 | 0.002 |
| Bladder operation ( | 1.118 | 0.830–1.508 | 0.463 |
| Prostate operation ( | 1.729 | 1.145–2.612 | 0.009 |
| Ureter operation ( | 1.634 | 0.899–2.971 | 0.107 |
| Kidney operation ( | 1.339 | 1.099–1.632 | 0.004 |
HR, hazard ratio, CI, confidence interval, eGFR, estimated glomerular filtration rate (mL/min/1.73 m2)
aAdjusted with organ of surgery (bladder, prostate, ureter, kidney), surgery type (open, laparoscopic, endoscopic, and robot-assisted surgery), age, sex, history of hypertension, diabetes mellitus, preoperative severe anemia, intraoperative use of normal saline, preoperative and postoperative serum creatinine level.